1. Clinical Overview
A fixed-dose combination (FDC) of three distinct pharmacological agents designed for comprehensive secondary prevention of atherothrombotic events, particularly in patients with established cardiovascular disease (CVD) or post-acute coronary syndrome (ACS). Aspirin and Clopidogrel provide synergistic antiplatelet action via different pathways (dual antiplatelet therapy - DAPT), while Atorvastatin provides intensive lipid-lowering and plaque-stabilizing effects. This combination is a cornerstone of secondary prevention strategies in India, aiming to improve adherence and reduce the risk of recurrent myocardial infarction (MI), stroke, and cardiovascular death.
| Onset | Duration | Bioavailability |
|---|---|---|
| Aspirin: 30-60 minutes (irreversible effect on platelets). Atorvastatin: LDL-C reduction begins in 2 weeks, maximal effect in 4 weeks. Clopidogrel: Active metabolite peaks in plasma at approximately 45 minutes after a 75mg dose, but significant platelet inhibition may take 3-7 days with loading dose, or up to 5 days without loading dose. | Aspirin: 7-10 days (lifespan of platelets). Atorvastatin: ~24 hours (once-daily dosing). Clopidogrel: 5-7 days (irreversible platelet inhibition). | Aspirin: ~50% (rapidly hydrolyzed to salicylate in gut/liver). Atorvastatin: ~14% (extensive first-pass metabolism). Clopidogrel: ~50% (requires hepatic activation to active metabolite). |
2. Mechanism of Action
This combination exerts a triple-action mechanism: 1) Anti-inflammatory & Antiplatelet (Aspirin): Irreversibly acetylates platelet cyclooxygenase-1 (COX-1), inhibiting thromboxane A2 (TXA2) synthesis, a potent platelet aggregator and vasoconstrictor. 2) Lipid Modification & Plaque Stabilization (Atorvastatin): Competitively inhibits HMG-CoA reductase, the rate-limiting enzyme in hepatic cholesterol synthesis, leading to upregulation of LDL receptors and increased clearance of LDL-C from blood. It also has pleiotropic effects (improved endothelial function, anti-inflammatory, plaque stabilization). 3) Alternative Antiplatelet Pathway Inhibition (Clopidogrel): Irreversibly inhibits the P2Y12 subtype of ADP receptor on platelet surface, preventing ADP-mediated activation of the GPIIb/IIIa complex and subsequent platelet aggregation. The dual antiplatelet action (Aspirin + Clopidogrel) provides synergistic inhibition of platelet aggregation.
3. Indications & Uses
- Secondary prevention of atherothrombotic events in patients with established Coronary Artery Disease (CAD)
- Post-Acute Coronary Syndrome (ACS: Unstable Angina, NSTEMI, STEMI) management after the initial phase
- Post-percutaneous coronary intervention (PCI) with stent implantation (typically for recommended DAPT duration)
- Secondary prevention in patients with history of ischemic stroke or Transient Ischemic Attack (TIA)
4. Dosage & Administration
Adult Dosage: One tablet (Aspirin 75mg + Atorvastatin 20mg + Clopidogrel 75mg) orally once daily. For post-ACS/PCI, a Clopidogrel loading dose (300mg or 600mg) may be given separately before initiating this FDC. Atorvastatin dose may be uptitrated to 40mg or 80mg based on lipid goals and tolerance, requiring separate prescriptions.
Administration: Administer once daily, with or without food. Evening administration may be preferred for Atorvastatin due to theoretical circadian rhythm of cholesterol synthesis, but clinical significance is minimal. Tablet should be swallowed whole with a glass of water. Do not crush or chew. If a dose is missed, take it as soon as remembered. If it is near the time for the next dose, skip the missed dose. Do not double the dose.
5. Side Effects
Common side effects may include:
- Dyspepsia, heartburn, epigastric discomfort (Aspirin)
- Headache, dizziness
- Nausea, diarrhea, constipation
- Myalgia (muscle pain - Atorvastatin)
- Increased bleeding tendency (bruising, epistaxis, gingival bleeding)
- Fatigue
6. Drug Interactions
| Drug | Effect | Severity |
|---|---|---|
| Warfarin / DOACs (Apixaban, Rivaroxaban, Dabigatran) | Profoundly increased risk of major and fatal bleeding. | Contraindicated / High |
| NSAIDs (Ibuprofen, Diclofenac, Naproxen) | Increased GI bleeding risk, may antagonize Aspirin's antiplatelet effect. | High |
| Proton Pump Inhibitors (Omeprazole, Esomeprazole) | Omeprazole/Esomeprazole are CYP2C19 inhibitors, may reduce Clopidogrel's efficacy. Pantoprazole is preferred. | Moderate |
| Strong CYP3A4 Inhibitors (Itraconazole, Ketoconazole, Clarithromycin, HIV protease inhibitors) | Increase Atorvastatin levels, high risk of myopathy/rhabdomyolysis. | High |
| Other Antiplatelets (Ticagrelor, Prasugrel) | Excessive antiplatelet effect, severe bleeding risk. | Contraindicated / High |
| SSRIs (Fluoxetine, Sertraline) | Increased bleeding risk due to impaired platelet serotonin uptake. | Moderate |
| Corticosteroids (Prednisolone) | Increased GI ulceration and bleeding risk. | Moderate |
| Grapefruit Juice | Inhibits CYP3A4, can increase Atorvastatin levels and risk of myopathy. | Moderate |
7. Patient Counselling
- DO take the tablet exactly as prescribed, at the same time each day.
- DO inform all your doctors and dentists about this medication before any surgery or procedure.
- DO report any unusual bleeding (nosebleeds, black/tarry stools, blood in urine/vomit, excessive bruising) immediately.
- DO get regular blood tests (lipid profile, LFTs) as advised by your doctor.
- DONT stop taking this medicine suddenly without consulting your doctor, as it may increase risk of heart attack or stroke.
- DONT take any other NSAIDs (like Ibuprofen, Diclofenac) for pain relief without asking your doctor. Paracetamol is usually safe.
- DONT consume alcohol regularly.
- DONT take any new prescription, OTC, or herbal medicine without checking for interactions.
8. Toxicology & Storage
Overdose: ASPIRIN: Tinnitus, vertigo, headache, confusion, hyperventilation, fever, sweating, nausea/vomiting, metabolic acidosis, respiratory alkalosis, coma, cardiovascular collapse. ATORVASTATIN: Elevated LFTs, myalgia, potential for severe rhabdomyolysis with renal failure. CLOPIDOGREL: Bleeding complications, prolonged bleeding time.
Storage: Store below 30°C, in a cool, dry place. Protect from light and moisture. Keep the bottle tightly closed. Keep out of reach and sight of children. Do not use after the expiry date printed on the pack.